Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the...

Related Keywords

Saclay ,France General ,France ,United States ,Paris ,Chicago ,Illinois ,American ,Ania Diantonio ,Institut Gustave Roussy ,Kiran Patel ,Janssen Pharmaceutica ,Yohann Loriot ,None Of The Janssen Pharmaceutical Companies ,Janssen Biotech Inc ,Astex Pharmaceuticals ,Drug Administration ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,American Society Of Clinical Oncology Annual Meeting ,Us Food Drug Administration ,Companies Of Johnson ,University Of Paris ,Johnson ,Clinical Development ,Clinical Oncology Annual ,Vice President ,Solid Tumors ,Janssen Research ,Bacillus Calmette Gu ,Soft Tissue Mineralization ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Transduct Target ,Rev Clin ,Clin Cancer ,Accessed June ,Erdafitinib Compared With Vinflunine ,Participants With Advanced Urothelial Cancer ,Selected Fibroblast Growth Factor Receptor ,Erdafitinib Versus Investigator Choice ,Participants Who Received Bacillus Calmette Gu ,The Janssen Pharmaceutical Companies Of Johnson Amp ,